Понимание социального бремени многочисленных склерозов в Грузии: всеобъемлющий анализ качества жизни и социально-демографических факторов.
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Khutsishvili Natalia, Ganugrava Nino, Janelidze Marina, Vashadze Tamar, Kiziria Marina, Megrelishvili Marika, Tsiskaridze Alexander
Аннотация
Оригинал публикации
Understanding the social burden of multiple sclerosis patients in Georgia: a comprehensive analysis of quality of life and sociodemographic factors.
BACKGROUND AND OBJECTIVES: Multiple sclerosis (MS) is a chronic autoimmune disorder that significantly impacts individuals' quality of life and imposes a substantial social burden on patients and society. Despite its global socioeconomic implications, limited research has focused on the social burden of MS. This study aimed to assess the social burden of MS in Georgia by evaluating the health-related quality of life of MS patients and exploring the correlation between disease burden and quality of life.
METHODOLOGY: This cross-sectional study was performed to assess the social burden of the disease by evaluating the impact of the disease on the quality of life of 384 patients with MS. The Multiple Sclerosis Quality of Life-54 questionnaire was administered to assess quality of life.
RESULTS: The Expanded Disability Status Scale score was significantly negatively correlated with the physical health composite score (r = -0.249, P < .001) and the general quality of life score (r = -0.220, P < .001). The quality of life was highly associated with gender, employment status, living/residence place, and moderately with age.
CONCLUSIONS AND IMPLICATIONS: This study revealed the intricate interplay between disability, quality of life, and sociodemographic factors among Georgian MS patients. The results of the study highlight the need for specialized therapies, networks of support, and public health initiatives to lessen the societal cost of MS.